IN THE CLAIMS

1-3. (cancelled)

4. (twice amended) A method for ~~screening for~~ testing treatments of neurodegenerative disease comprising:

inducing protein aggregation in a first sample comprising NACP/α-synuclein by exposing a first sample to an oxidizing agent ~~of amyloidogenic proteins~~;

exposing the first sample ~~amyloidogenic proteins~~ to a treatment;

inducing protein aggregation in a second sample comprising NACP/α-synuclein by exposing a second sample to the oxidizing agent;

measuring an aggregation level of NACP/α-synuclein in the first sample and the second sample;

and ~~measuring~~ comparing the aggregation level of NACP/α-synuclein in the first sample and with the aggregation level of NACP/α-synuclein in the second sample ~~to test for a decrease in aggregation~~, wherein ~~the decrease~~ less aggregation in the first sample is indicative of an effective treatment.

5. (twice amended) The method of claim 4 ~~11~~, wherein the oxidizing agent comprises ~~oxidative stress is stimulated by~~ a mixture of metal-ions and hydrogen peroxide.

6. (twice amended) The method of claim 4 ~~11~~, wherein the oxidizing agent comprises a product of ~~oxidative stress is stimulated using~~ an iron-catalyzed oxidative reaction.

7. (twice amended) The method of claim 4, wherein the treatment comprises ~~expression of~~ a non-amyloidogenic protein that modulates aggregation of NACP/α-

synuclein.

8. (original) The method of claim 7, wherein the non-amyloidogenic protein is β-synuclein.

9-11. (cancelled)

12. (previously presented) The method of claim ~~4~~ 14, wherein the treatment comprises an agent to promote the expression of anti-amyloidogenic proteins.

13. (previously presented) The method of claim 12, wherein the anti-amyloidogenic protein is β-synuclein.

14. (new) The method of claim 4, wherein the first sample comprises cells that express NACP/α-synuclein.

15. (new) The method of claim 14, wherein the cells are neuronal cells.